DDInter1432 DDInter1376
An antipsychotic phenothiazine derivative with actions and uses similar to those of chlorpromazine.
Ozanimod is a once-daily sphingosine 1-phosphate receptor modulator for the treatment of relapsing Multiple Sclerosis (MS) and inflammatory bowel disease. It was developed by Celgene (now acquired by Bristol-Myers Squibb) and was approved by the FDA on March 26, 2020.[L12573,L12582] The US approval was followed by the approval in Canada on October 2, 2020. In November 2021, ozanimod was also approved by the European Commission for the treatment of adults with relapsing remitting multiple sclerosis.[L39377,L39382] MS is a devastating inflammatory disease that often progresses and causes severe neurological, physical, and cognitive effects. Inflammatory bowel disease also a chronic inflammatory condition and can cause persistent abdominal pain, diarrhea, bloody stools, and vomiting. In clinical trials, Ozanimod has been shown to be well-tolerated and has resulted in a higher decrease in the rate of MS relapses than with intramuscular [interferon beta-1a], a current standard in MS therapy. Studies involving patients with inflammatory bowel disease have also shown promising results.[A189318,A189342]
Perphenazine {u} (Compound) resembles {v} (Compound) Triflupromazine
Perphenazine {u} (Compound) resembles {v} (Compound) Propericiazine
Perphenazine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Cetirizine
Perphenazine {u} (Compound) binds {v} (Gene) CYP2C18
Perphenazine {u} (Compound) upregulates {v} (Gene) ST3GAL5
Perphenazine {u} (Compound) palliates {v} (Disease) Gilles de la Tourette syndrome
Perphenazine {u} (Compound) is included by {v} (Pharmacologic Class) Phenothiazines
Perphenazine {u} (Compound) downregulates {v} (Gene) TXNDC9
Perphenazine {u} (Compound) causes {v} (Side Effect) Nocturnal confusion
Perphenazine {u} may cause a minor interaction that can limit clinical effects when taken with {v} Sucralfate
Perphenazine (Compound) resembles Triflupromazine (Compound)
Perphenazine (Compound) resembles Propericiazine (Compound)
Perphenazine may cause a moderate interaction that could exacerbate diseases when taken with Cetirizine
Perphenazine (Compound) binds CYP2C18 (Gene)
Perphenazine (Compound) upregulates ST3GAL5 (Gene)
Perphenazine (Compound) palliates Gilles de la Tourette syndrome (Disease)
Perphenazine (Compound) is included by Phenothiazines (Pharmacologic Class)
Perphenazine (Compound) downregulates TXNDC9 (Gene)
Perphenazine (Compound) causes Nocturnal confusion (Side Effect)
Perphenazine may cause a minor interaction that can limit clinical effects when taken with Sucralfate